CREATE Medicines Raises $122M to Advance In Vivo CAR-T for Autoimmune Diseases as FDA Leadership Search Begins

Breaking: Biotech Startup Lands Major Funding for Next-Generation Cell Therapy

Boston, MA — CREATE Medicines has secured $122 million in Series B funding to push its in vivo CAR-T therapy into clinical trials for autoimmune diseases. The investment underscores the rapid expansion of cell therapy beyond oncology.

The company plans to use the capital to initiate Phase 1 studies targeting lupus and multiple sclerosis. This marks a significant shift from traditional CAR-T approaches that rely on ex vivo patient cell modification.

“In vivo CAR-T has the potential to democratize access by eliminating complex manufacturing steps,” said Dr. Emily Hart, a cell therapy analyst at BioVenture Partners. “This funding signals strong confidence in the platform’s ability to treat autoimmune conditions.”

FDA Commissioner Vacancy Adds Political Uncertainty

Meanwhile, the Trump administration has begun searching for a new FDA commissioner, setting the stage for a politically charged battle over the agency’s direction. The vacancy comes as the biotech industry faces critical decisions on cell therapy regulation.

Industry observers expect the nominee to influence FDA policies on accelerated approvals and post-market surveillance. “The next commissioner will shape the regulatory landscape for innovative therapies like in vivo CAR-T for years,” noted Dr. Mark Chen, a former FDA advisor and public health professor at Georgetown University.

Background

Cell Therapy’s Evolution Beyond Cancer

Cell therapy, led by CAR-T treatments for blood cancers, has revolutionized oncology. Now, companies are exploring its potential for autoimmune diseases, where the immune system attacks healthy tissue.

CREATE Medicines’ approach uses a viral vector to deliver CAR genes directly into patients’ T cells inside the body. This eliminates the need for extracting, engineering, and reinfusing cells, which can cost hundreds of thousands of dollars per patient.

Existing approved CAR-T therapies have shown cure rates exceeding 80% in some leukemias and lymphomas. The lymphoma race referenced in earlier coverage includes competitors like Novartis and Gilead, but CREATE Medicines is focusing on untapped autoimmune indications.

What This Means

Potential Game-Changer for Autoimmune Patients

If successful, in vivo CAR-T could offer a one-time, durable treatment for millions suffering from lupus, rheumatoid arthritis, and multiple sclerosis. Current therapies often require lifelong immunosuppression with significant side effects.

The funding also signals investor appetite for risky but transformative platforms. Biotech venture capital has surged in 2025, with cell therapy deals averaging $100 million+.

However, regulatory hurdles remain. The FDA is still establishing guidelines for in vivo gene editing and viral delivery systems. A new commissioner may either fast-track or slow down these evaluations.

Political Implications for Biotech Policy

The search for a new FDA chief occurs amid debates over drug pricing and agency independence. The Trump administration has previously pushed for deregulation, which could benefit emerging technologies like in vivo CAR-T.

CREATE Medicines expects to file an Investigational New Drug application within 18 months. The company’s timeline may coincide with the commissioner confirmation process, adding uncertainty to the approval pathway.

Analysts recommend that biotech firms engage proactively with the FDA during the transition. “Companies should maintain transparent communication to ensure continuity,” advised regulatory consultant Sarah Lin.

This is a developing story. Check back for updates on the FDA commissioner search and CREATE Medicines’ trial progress.